Clinical Trial Information
Monotherapy versus Sacituzumab Govitecan in Combination with MK-3475 for PD-L1 TPS =50% Metastatic NSCLC- Category: Lung Cancer
- Status: Active
- Starts: Jun 1, 2023
- Stage: III
- Trial Number: KEYNOTE D46-02
Description of Trial:
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-
Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
NCT05609968
Please click here for additional information.